Acute Coronary Syndrome (ACS) represents a spectrum of conditions associated with acute myocardial ischemia. As our understanding of the pathophysiology of ACS has evolved, so too have the strategies for its management. This article aims to provide an overview of the latest advancements and best practices in managing ACS.
Over the past decade, significant advancements have been made in the management of ACS. The introduction of high-sensitivity cardiac troponin assays has improved the early diagnosis of ACS. Furthermore, the advent of novel antiplatelet agents such as ticagrelor and prasugrel has enhanced the efficacy of dual antiplatelet therapy, reducing the risk of recurrent ischemic events.
Best practices in ACS management are guided by evidence-based clinical guidelines. Early risk stratification using tools such as the GRACE score is recommended to guide treatment decisions. For patients with ST-elevation myocardial infarction (STEMI), immediate reperfusion therapy is the standard of care. For non-STEMI patients, an early invasive strategy is preferred, particularly for those at high risk. Long-term management includes optimal medical therapy, secondary prevention measures, and cardiac rehabilitation.
Future research in ACS management is directed towards individualized patient care. This includes the development of precision medicine approaches, utilizing genomic and proteomic data to guide treatment decisions. Additionally, the role of novel imaging modalities in improving risk stratification and guiding revascularization strategies is being explored.
In conclusion, the management of ACS has substantially evolved over the past decade, with significant advancements in diagnostic and therapeutic strategies. Adherence to evidence-based best practices is crucial to improve patient outcomes. Future directions in ACS management include the development of precision medicine approaches and the use of novel imaging modalities.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation